PRIMOMED
Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs
| Coordinatore | AMAKEM NV
Organization address
address: AGORALAAN GEBOUW ABIS BIOVILLE contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 1˙602˙769 € |
| EC contributo | 1˙234˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2013 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
AMAKEM NV
Organization address
address: AGORALAAN GEBOUW ABIS BIOVILLE contact info |
BE (DIEPENBEEK) | coordinator | 320˙235.00 |
| 2 |
COMPLIX NV
Organization address
address: AGORALAAN BUILDING A-BIS contact info |
BE (DIEPENBEEK) | participant | 374˙599.00 |
| 3 |
MIND-NRG SA
Organization address
address: RUE DE JARGONNANT 2 contact info |
CH (GENEVE) | participant | 354˙550.00 |
| 4 |
FAST FORWARD PHARMACEUTICALS BV
Organization address
address: YALELAAN 46 contact info |
NL (UTRECHT) | participant | 172˙616.00 |
| 5 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 6˙000.00 |
| 6 |
STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Organization address
address: LANGE KLEIWEG 161 contact info |
NL (RIJSWIJK ZH) | participant | 6˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives of the project are (1) to demonstrate proof of concept that drug compounds of the SME’s are efficacious in primate models relevant for the diseases of interest and (2) to determine the immune responses in biological samples generated by the research activities in the different animal models. The power of the Primomed project is the creation of a consortium bringing together four small and early-stage biotech companies owning innovative and proprietary drugs and two of the most renowned European primate research centres that will perform research activities with the new disease modifying molecules of the SME’s. The disease areas of interest in Primomed are asthma, multiple sclerosis and Parkinson disease. Amakem’s Localized Drug Action approach would allow the use of ROCK inhibitors for the treatment of respiratory diseases, e.g. asthma, while avoiding the side effects resulting from systemic ROCK inhibition. By selectively targeting IL-23p19, Complix’ Alphabody is an intriguing candidate for therapy development of asthma and MS and may avoid some of the severe side effects of other currently available and tested anti-IL12/IL23p40 therapies. FFP’s PG102 would be a first in class molecule with a novel mechanism of action in treating chronic inflammatory conditions such as MS. sNRG would be a protein drug with disease modifying potential for the treatment of an unmet medical need in Parkinson’s disease. Primomed will result in progressing the compounds to the clinic, maximize the chance at eventual market authorization and answer the unmet medical need of millions of patients.'
Altri progetti dello stesso programma (FP7-SME)
ICYHEART (2011)
Highly integrated ultra-low-power SoC solution for unobtrusive and energy-efficient wireless cardiac monitoring
Read MoreHYDRUS (2009)
Development of crosslinked flexible bio-based and biodegradable pipe and drippers for micro-irrigation applications
Read MoreRADI-CAL (2009)
Development of an innovative, accurate, monolithic 2D CVD Diamond based radiation dosimetry system for conformal radiotherapy solutions
Read More